Vandetanib
Tocris Bioscience, part of Bio-Techne | Catalog # 7497
Potent VEGFR-2 inhibitor, also inhibits EGFR and RET oncoproteins activity
Key Product Details
Description
Potent VEGFR-2 inhibitor, also inhibits EGFR and RET oncoproteins activity
Product Description
Vandetanib is a potent VEGFR-2 inhibitor (IC50 = 0.04 μM), and inhibitor of EGFR (IC50 = 0.5 μM). Vandetanib potently inhibits (IC50 = 100 nM) RET oncoprotein activity in human thyroid cancer. Vandetanib displays anti-angiogenic properties in human nasopharyngeal carcinoma in mice model. Vandetanib is orally available and effective in vivo.Product Specifications
Molecular Weight
475.36
Formula
C22H24BrFN4O2
Storage
Store at -20°C
Purity
≥98% (HPLC)
Chemical Name
N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine
CAS Number
443913-73-3
PubChem ID
3081361
InChI Key
UHTHHESEBZOYNR-UHFFFAOYSA-N
SMILES
FC1=CC(Br)=CC=C1NC=2N=CN=C3C=C(OCC4CCN(C)CC4)C(OC)=CC32
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 23.77 | 50 |
Preparing Stock Solutions
for Vandetanib
The following data is based on the product molecular weight 475.36
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.5 mM | 4.21 mL | 21.04 mL | 42.07 mL |
| 2.5 mM | 0.84 mL | 4.21 mL | 8.41 mL |
| 5 mM | 0.42 mL | 2.10 mL | 4.21 mL |
| 25 mM | 0.08 mL | 0.42 mL | 0.84 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Hennequin Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J.Med.Chem. 2002 PMID: 11881999
- Cui Resonance imaging for monitoring the early response to ZD6474 from nasopharyngeal carcinoma in nude mouse. Sci.Rep. 2015 PMID: 26574153
- Ancker Multikinase inhibitor treatment in thyroid cancer. Int.J.Mol.Sci. 2019 PMID: 31861373
- Carlomagno ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer res. 2002 PMID: 12499271
Product Specific Notices for Vandetanib
For research use only
Loading...
Loading...